Clinical trial
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced…
NCT00079053 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00079053 |
|---|---|
| Title | Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
| Official title | A Phase I Study of Adjuvant OSI-774 (Tarceva®) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Procedure |
| Interventions | erlotinib hydrochloride, adjuvant therapy |
| Enrollment | 19 |
| Start date | Mar 2, 2004 |
| Primary completion | Dec 9, 2008 |
| Completion | Jan 18, 2011 |
| First posted | Mar 9, 2004 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: